Acytronix revolutionizes the purification of extracellular vesicles with a mission to advance diagnostics and therapeutics.
Extracellular vesicles (EVs) are nano-sized vesicles secreted by cells in our body. They are bioactive, represent the original tissue, and are distributed in bodily fluids.

They are recognized as next-generation biomarkers and therapeutic agents. However, the need to initially isolate them from the complex native matrix limits their biomedical application.

Acytronix is an ETH spin-off based in Schlieren. The management team includes CTO Dr. Vadim Krivitsky and CEO Dr. Adva Krivitsky, with Prof. Jean-Christophe Leroux as the scientific advisor. They have developed a portable, easy-to-use device for the isolation of EVs from raw physiological fluids. This patent-protected device represents significant progress compared to conventional methods for EVs isolation, as it enables high-throughput isolation of EVs sub-populations according to surface marker expression, designed to advance EV-based liquid biopsy. Moreover, it uniquely offers the option to load the EVs with therapeutics on a single platform for drug delivery applications.